Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a single-center experience with 854 patients

Author: Ao XIA ¹
Author Information

1. Department of Pseudomyxoma Peritonei
Publication Type:Journal Article
Keywords: Cytoreductive surgery (CRS); Hyperthermic intraperitoneal chemotherapy (HIPEC); Maximal tumor reduction; Modified peritoneal cancer index; Peritoneal resection; Pseudomyxoma peritonei (PMP)
From: Chinese Journal of Clinical Oncology 2020;47(3):145-151
CountryChina
Language:Chinese
Abstract: Pseudomyxoma peritonei (PMP) is a rare clinical syndrome. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is gradually being accepted as the standard treatment for PMP. At Aerospace Hospital, we have been treating patients with PMP since 2008 and performing total peritoneal resection since 2016. This study summarizes the experience at our center and collates past data. Methods: We performed a retrospective analysis of a prospectively maintained database of all patients who had undergone CRS and HIPEC for PMP at our center. Clinical data, such as the surgical approach, completeness of cytoreduction, and surgical complications, were collected. The results from follow-up were analyzed to simultaneously evaluate the clinical value of CRS+HIPEC and peritonectomy procedures. Results: A total of 854 consecutive patients with PMP were included in the study. Their mean age was 50 years. The median modified peritoneal cancer index (PCI) was 29. Of the patients, 25.5% under-